Kristin Baltrusaitis

Biography

Kristin Baltrusaitis, PhD, is a Research Scientist at the Center for Biostatistics in AIDS Research (CBAR), Harvard T.H. Chan School of Public Health. As a Research Scientist, she contributes to the study design, monitoring, and analysis of multiple studies that evaluate prevention and treatment interventions for HIV and HIV-associated complications and co-morbidities in infants, children, and adolescents, and during pregnancy and postpartum. Her primary independent research interests are in pediatric Phase I/II clinical trial design, sensitivity analyses for missing data in cluster randomized trials, and growth and developmental outcomes in children who are HIV-exposed but uninfected (CHEU).

Education and Training

• BS, Biochemistry
  Lehigh University
• PhD, Biostatistics
  Boston University
• MS, Mathematics Education
  Brooklyn College

Publications

• Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.

  Moore CB, Baltrusaitis K, Best BM, Moye JH, Townley E, Violari A, Heckman B, Buisson S, Van Solingen-Ristea RM, Capparelli EV, Marzinke MA, Lowenthal ED, Ward S, Krotje C, Milligan R, Agwu AL, Huang J, Cheung SYA, McCoig C, Yin DE, Roberts G, Crauwels H, Van Eygen V, Zabih S, Masheto G, Ounchanum P, Aurpibul L, Korutaro V, Gaur AH. Lancet HIV 2025

  PMID: 40049924

• Participant acceptability and clinician satisfaction of cognitive behavioural therapy and medication management algorithm compared with enhanced standard care for treatment of depression among youth with HIV.

  Barr EA, Baltrusaitis K, Kennard BD, Emslie GJ, Krotje C, Knowles K, Buisson S, Bergam L, Deville JG, Gillespie SL, Shikora M, Townley E, Shapiro DE, Brown LK. J Child Adolesc Ment Health 2024 Nov 17

  PMID: 39550758

• Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032.

  Brooks KM, Baltrusaitis K, Clarke DF, Nachman S, Jao J, Purswani MU, Agwu A, Beneri C, Deville JG, Powis KM, Stek AM, Eke AC, Shapiro DE, Capparelli E, Greene E, George K, Yin DE, Jean-Philippe P, Chakhtoura N, Bone F, Bacon K, Johnston B, Reding C, Kersey K, Humeniuk R, Best BM, Mirochnick M, Momper JD. J Infect Dis 2024 Oct 16

  PMID: 38839047

• Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.

  Gaur AH, Capparelli EV, Calabrese K, Baltrusaitis K, Marzinke MA, McCoig C, Van Solingen-Ristea RM, Mathiba SR, Adeyeye A, Moye JH, Heckman B, Lowenthal ED, Ward S, Milligan R, Samson P, Best BM, Harrington CM, Ford SL, Huang J, Crauwels H, Vandermeulen K, Agwu AL, Smith-Anderson C, Camacho-Gonzalez A, Ounchanum P, Kneebone JL, Townley E, Bolton Moore C. Lancet HIV 2024

  PMID: 38538160

• Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.

  Lowenthal ED, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, Yin DE, Agwu AL, Harrington C, Van Solingen-Ristea RM, McCoig CC, Adeyeye A, Kneebone J, Chounta V, Smith-Anderson C, Camacho-Gonzalez A, D'Angelo J, Bearden A, Crauwels H, Huang J, Buisson S, Milligan R, Ward S, Bolton-Moore C, Gaur AH. Lancet HIV 2024

  PMID: 38538161